Literature DB >> 16669604

Niacin improved rigidity and bradykinesia in a Parkinson's disease patient but also caused unacceptable nightmares and skin rash--a case report.

Joseph Martin Alisky1.   

Abstract

A patient with Parkinson's disease taking levodopa/carbidopa, selegiline, buproprion, aspirin and niacin had decreased rigidity and bradykinesia when his niacin dose was steadily escalated for treatment of high triglycerides, but ultimately the patient could not tolerate niacin because of severe nightmares and skin rash. If further research can reproduce this patient's initial beneficial experience while avoiding the adverse effects, niacin could be a useful adjunctive agent for Parkinson's disease, either population-wide or in a pharmacogenomically defined set of responders.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16669604     DOI: 10.1080/10284150500484638

Source DB:  PubMed          Journal:  Nutr Neurosci        ISSN: 1028-415X            Impact factor:   4.994


  12 in total

Review 1.  Therapeutic Potential of NAD-Boosting Molecules: The In Vivo Evidence.

Authors:  Luis Rajman; Karolina Chwalek; David A Sinclair
Journal:  Cell Metab       Date:  2018-03-06       Impact factor: 27.287

Review 2.  NAD+ in Brain Aging and Neurodegenerative Disorders.

Authors:  Sofie Lautrup; David A Sinclair; Mark P Mattson; Evandro F Fang
Journal:  Cell Metab       Date:  2019-10-01       Impact factor: 27.287

Review 3.  PGC-1α, Sirtuins and PARPs in Huntington's Disease and Other Neurodegenerative Conditions: NAD+ to Rule Them All.

Authors:  Alejandro Lloret; M Flint Beal
Journal:  Neurochem Res       Date:  2019-05-07       Impact factor: 3.996

Review 4.  Oral nicotinamide for non-melanoma skin cancers: A review.

Authors:  Samantha Vicki Hunt; Aaron Jamison; Raman Malhotra
Journal:  Eye (Lond)       Date:  2022-03-28       Impact factor: 4.456

5.  Low-dose niacin supplementation modulates GPR109A, niacin index and ameliorates Parkinson's disease symptoms without side effects.

Authors:  Chandramohan Wakade; Raymond Chong; Eric Bradley; John C Morgan
Journal:  Clin Case Rep       Date:  2015-06-11

6.  Upregulation of GPR109A in Parkinson's disease.

Authors:  Chandramohan Wakade; Raymond Chong; Eric Bradley; Bobby Thomas; John Morgan
Journal:  PLoS One       Date:  2014-10-17       Impact factor: 3.240

7.  Decreased NAD+ in dopaminergic neurons.

Authors:  Samantha L Sison; Allison D Ebert
Journal:  Aging (Albany NY)       Date:  2018-04-28       Impact factor: 5.682

Review 8.  The Influence of Nicotinamide on Health and Disease in the Central Nervous System.

Authors:  Rosemary A Fricker; Emma L Green; Stuart I Jenkins; Síle M Griffin
Journal:  Int J Tryptophan Res       Date:  2018-05-21

Review 9.  Role of Dietary Supplements in the Management of Parkinson's Disease.

Authors:  Michele Ciulla; Lisa Marinelli; Ivana Cacciatore; Antonio Di Stefano
Journal:  Biomolecules       Date:  2019-07-10

Review 10.  Niacin and Butyrate: Nutraceuticals Targeting Dysbiosis and Intestinal Permeability in Parkinson's Disease.

Authors:  Tennekoon B Karunaratne; Chijioke Okereke; Marissa Seamon; Sharad Purohit; Chandramohan Wakade; Amol Sharma
Journal:  Nutrients       Date:  2020-12-23       Impact factor: 5.717

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.